The Global Antibiotic Research & Development Partnership (GARDP) and the Stop TB Partnership’s Global Drug Facility (GDF) announced a partnership agreement to improve global access to antibiotics. GDF will incorporate GARDP’s portfolio of antibiotics to improve appropriate and affordable antibiotic access for the benefit of patients and health systems, particularly in low- and middle-income countries.

Its goal is to ensure the continued worldwide standardization of TB surveillance, in the context of WHO’s End TB Strategy, the latest WHO guidelines on TB screening, prevention, diagnosis and treatment, and commitments made at the 2023 UN High-Level Meeting on TB.

The Communities Delegation to the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria is currently inviting applications for membership from people living with HIV, and affected by TB or malaria. The selection process strives to achieve a balanced and representative Delegation.

A Stop TB Partnership-led delegation of TB survivors, researchers, communities and civil society representatives attended the Multi-stakeholder Hearing on AMR to push for the inclusion of TB in the upcoming AMR Political Declaration.

RESIST-TB will host a webinar on 30 May 2024 on endTB trial results. Dr. Mikanda Kunda, a Lesotho Principal Investigator for endTB trials and STEM-TB observational study, will be presenting.

On 15 May 2024, Treatment Action Group (TAG) hosted a webinar on TB diagnostics pipeline: New tools & opportunities to improve access to testing.

The guidance includes approaches to expanding the coverage, quality and impact of existing social protection programs to people affected by TB.

SMART4TB invites you to take part in a 15-minute diagnostic questionnaire, 'Understanding preferences for TB point-of-care diagnostics to inform the development of new tests'. It aims to understand the opinions of TB healthcare workers, policymakers, researchers, and affected communities regarding their priorities for bringing TB diagnosis closer to point-of-care for patients.

The International Union Against Tuberculosis and Lung Disease released the May 2024 issue of IJTLD OPEN – a fully-compliant, open access journal to enhance the coverage of TB and lung disease.